Investigators: Asha Bowen, Julie Marsh, Tom Snelling
External collaborators: Steven Tong (Menzies School of Health Research), Joshua Davis (Menzies School of Health Research)\
Staphylococcus aureus (golden staph) can cause sepsis and serious infections of the lungs, skin, bones and joints. In some cases, the staphylococcus bacteria produces toxins that can damage tissues and immune cells. Our overall aim is to determine whether adding an antibiotic called clindamycin to the treatment regimen to switch off toxin production improves outcomes for patients with these life threatening infections. This project is designed as a pilot study to determine the initial feasibility and safety of such an approach and will involve patients from hospitals around Australia. The pilot trial will inform the design of a larger study and logistics of patient recruitment, consent and data collection.